

Amendment List
The Modernizing and Ensuring PBM Accountability Act
July 26, 2023

Committee Number	Senator	Summary
1	Wyden #1	Placeholder/TBD
2	Wyden #2	Placeholder/TBD
3	Stabenow/Lankford #1	Mid-Year Formulary Changes for Biosimilars
4	Cantwell/Grassley/Menendez/ Daines #1	PBM Reporting Enhancements Under 1150A
5	Carper/Grassley #1	PBM Oversight Act of 2023: This Amendment would amend SSA Section 1860D-4 to require that P&T committees to report their recommendations for which drugs are included and excluded from health plans formulary to Centers for Medicare and Medicaid Services annually. Every fifth year Government Accountability Office would report trends to Congress
6	Carper/Grassley #2	P&T Committee Conflicts of Interest : This amendment would amend SSA Section 1860D-4 to require that at least one practicing physician and one practicing pharmacist is independent and free of conflict with respect to any pharmacy benefit manager.
7	Cardin/Cassidy #1	GAO Drug Shortage Study
8	Cardin/Cornyn #2	Streamlining the Part D Appeals Process
9	Bennet/Lankford #1	Prescription Drug Supply Chain Pricing Transparency Act
10	Bennet/Cornyn #2	Increasing Access to Biosimilars Act
11	Bennet #3	American Made Pharmaceuticals Act
12	Bennet/Blackburn #4	Rural Prescription Drug Costs Transparency Study
13	Casey/Cornyn #1	Protecting Seniors from High Drug Costs
14	Warner/Lankford #1	Relevance Determinations related to Pharmacy Quality Measures

Amendment List
The Modernizing and Ensuring PBM Accountability Act
July 26, 2023

15	Warner/Thune/ Cortez Masto/Tillis #2	PBM Reporting Transparency Act
16	Warner/Cassidy #3	To establish an acquisition cost and dispensing fee survey and reporting regimen specific to certain non-retail pharmacies.
17	Hassan/Lankford #1	Enhanced PBM Reporting Requirements Related to Generics & Biosimilars
18	Hassan #2	Report on Medicare Beneficiary Out-of-Pocket Costs for Off-Campus Drug Administration
19	Cortez Masto/Young #1	Biennial Report on Inappropriate Pharmacy Rejections
20	Cortez Masto #2	Enhance oversight of pharmacy rejections
21	Warren #1	Addressing Vertical Integration in the Drug Supply Chain
22	Warren #2	Establishing Formulary Integrity
23	Warren #3	Eliminating Anti-Competitive Gaming by Drug Manufacturers
24	Warren #4	Increasing Transparency of PBM Practices
25	Warren #5	Strengthening Oversight of PBMs
26	Warren #6	Expanding Enforcement Authority to Ensure PBM Compliance
27	Crapo #1	Placeholder/TBD
28	Crapo #2	Placeholder/TBD
29	Grassley/Menendez/Blackburn #1	Pharmacy benefit manager accountability and compliance to delinking provision
30	Grassley #2	To protect competition and access to rural and independent pharmacies during DIR fee clawback changes
31	Grassley/Brown #3	Drug price transparency for consumers in prescription drug advertisements
32	Grassley/Brown/Casey #4	To encourage pharmacists to serve older Americans in communities that lack easy access to doctors or where pharmacists are able to provide certain basic medical services
33	Grassley #5	Reporting PBM Enhancements under 1150A
34	Grassley #6	P&T Committee Conflicts of Interest
35	Cornyn/Carper/Tillis/Brown#1	Share the Savings with Seniors Act
36	Cornyn #2	Affordable Prescriptions for Patients Act
37	Cornyn #3	To be determined

Amendment List
The Modernizing and Ensuring PBM Accountability Act
July 26, 2023

38	Thune/Brown/Barrasso/ Stabenow #1	Strengthening Pharmacy Access for Seniors Act
39	Thune/Stebenow/Grassley #2	Improving patient and provider access to transparent drug pricing information through the use of real-time benefit tools (RTBTs)
40	Thune/Warner #3	Equitable Community Access to Pharmacist Services Act
41	Thune/Brown #4	To add clarifying requirements for 340B covered entities language to reporting
42	Thune/Carper #5	Chronic Disease Management Act
43	Scott/Warner #1	Initiating Meaningful Patient Review Of Various Existing Part D Regulations Act or IMPROVE Part D Regulations Act.
44	Cassidy #1	This amendment would create an exception from the Medicare Drug Price Negotiation Program for a manufacturer that makes industry-leading investments in R&D.
45	Lankford/Brown #1	Protect Patient Access to Pharmacies Act
46	Lankford/Menendez/Cornyn/ Hassan/Tillis/Bennet #2	Ensuring Access to Lower-Cost Medicines for Seniors Act
47	Lankford/Menendez #3	Biosimilar and Generic Access under Part D
48	Tillis #1	Adds OIG to Entities to which PBM-Reported Information May be Disclosed
49	Tillis/Daines/Blackburn/ Lankford #2	This amendment may be cited as the “The Safeguarding Patients and Taxpayers Act”
50	Blackburn #1	This amendment may be cited as the “Neighborhood Options for Patients Buying Medicines”
51	Blackburn/Brown #2	To ensure equal access of Medicare beneficiaries to community pharmacies in underserved areas as network pharmacies under Medicare prescription drug coverage
52	Blackburn #3	To clarify the application of the in-office ancillary exception to the physician self-referral prohibition for drugs furnished under the Medicare program
53	Blackburn/Lankford #4	To require a biannual report on enforcement and oversight of pharmacy access requirements